Welcome to Jianke online pharmacy! Sign in Free registration
reminder:The pictures are the real photos of the original products taken by Jianke for reference only; In case of new packaging listing, there may be update lag, please take the physical object as the standard!
Baidu certification

Kazuo double DOPA sustained release tablets (Xining)

·Primary Parkinson's disease. ·Parkinson's syndrome after encephalitis. ·Symptomatic Parkinson's syndrome (carbon monoxide or manganese poisoning). ·For patients who have previously used levodopa / decarboxylase inhibitor compound preparation or treated with levodopa alone with end-of-dose deterioration ("weakening" phenomenon), peak dose dyskinesia, dyskinesia, or similar short-term dyskinesia, the "off" time can be reduced. More role
App download minus 10 yuan
Common name:
Kazuo double DOPA sustained release tablets
Product No.:
B14202011289
Approval No.:
Gyzz j20160034 (inquired by the State Drug Administration)
Jianke price:
¥980.00
Product specification:
10 * 2 plates (50mg+200mg)*30s
Manufacturer:
Merck sharp & Dohme (Italy) Spa (sub packaged by Hangzhou MSD Pharmaceutical Co., Ltd.)

Warm tips, this product is out of stock now(you can book the product first,already existing0Person reservation

    Jianke promises:
    Genuine guarantee
    Bank remittance / transfer online payment
    • Product introduction
    • instructions
    • Qualification certificate
    • Relevant information
    Product name Kazuo double DOPA sustained release tablets (Xining)
    Main raw materials The main ingredients are carbidopa 50mg and levodopa 200mg.
    Main role ·Primary Parkinson's disease. ·Parkinson's syndrome after encephalitis. ·Symptomatic Parkinson's syndrome (carbon monoxide or manganese poisoning). ·For patients who have previously used levodopa / decarboxylase inhibitor compound preparation or treated with levodopa alone with end-of-dose deterioration ("weakening" phenomenon), peak dose dyskinesia, dyskinesia, or similar short-term dyskinesia, the "off" time can be reduced.
    Product specification (50mg+200mg)*30s
    Usage and dosage The ratio of carbidopa to levodopa in this product is 1:4. Each tablet contains 50mg carbidopa and 200mg levodopa. The daily dose of this product must be carefully adjusted and determined. During dose adjustment, patients should be closely monitored, especially the occurrence or aggravation of nausea or abnormal involuntary movement, including dyskinesia, chorea and dystonia. This product can be taken whole or half tablets. This method can maintain the sustained-release characteristics of the tablets and can not chew and crush the tablets. When taking this product, you can continue to take other standard anti Parkinson's disease drugs in addition to levodopa, but the dose needs to be adjusted. Because carbidopa can prevent the reversal of levodopa caused by pidoxin, this product can be used in patients receiving pidoxin supplementary treatment. At the same time, patients receiving pyridoxine supplement (vitamin B6) can take this product. Initial dose Patients not treated with levodopa: The recommended starting dose of this product is half a tablet twice a day. For patients who need more levodopa, take 1-4 half tablets a day in two times, generally well tolerated. This product can also be used for initial treatment when appropriate. The recommended starting dose of this product is 1 tablet 2 to 3 times a day. The starting dose of levodopa shall not be higher than 600mg per day or the interval between administration shall not be less than 6 hours. (see instructions for details)
    manufacturing enterprise Merck sharp & Dohme (Italy) Spa (sub packaged by Hangzhou MSD Pharmaceutical Co., Ltd.)
    Jianke commitment
    • Genuine guarantee, formal invoice

      Jianke.com is an approved (B2C) Internet drug legitimate business enterprise in Guangdong Province. It signs a direct supply agreement with the manufacturer and can issue formal invoices for the purchased goods.

    • Private packaging, privacy protection

      When jianke.com packages and delivers goods, the appearance of the packing box only displays the necessary information for delivery, and the name of the purchased goods will not appear. The specific shopping list is in the package to protect the privacy of customers.

    • Efficient logistics and safe arrival

      All products of jianke.com adopt the door-to-door distribution mode of third-party logistics. They are delivered to the nearest warehouse according to your distribution address, so as to deliver them to you on time.

    • Three warehouses to ensure inventory

      Jianke.com has three warehouses in Guangzhou, Dongguan and Wuhan, equipped with first-class equipment, constant temperature and humidity to ensure drug quality. Specially assigned person to manage and ensure product inventory.

    [drug name] Kazuo double DOPA sustained release tablets (Xining)

    [common name] Kazuo double DOPA sustained release tablets

    [specification and model] (50mg+200mg)*30s

    [manufacturer] Merck sharp & Dohme (Italy) Spa (sub packaged by Hangzhou MSD Pharmaceutical Co., Ltd.)

    [drug type] Western medicine

    [approval No.] Gyzz j20160034

    [validity period] 36 months

    [functional indications] ·Primary Parkinson's disease. ·Parkinson's syndrome after encephalitis. ·Symptomatic Parkinson's syndrome (carbon monoxide or manganese poisoning). ·For patients who have previously used levodopa / decarboxylase inhibitor compound preparation or treated with levodopa alone with end-of-dose deterioration ("weakening" phenomenon), peak dose dyskinesia, dyskinesia, or similar short-term dyskinesia, the "off" time can be reduced.

    [usage and dosage] The ratio of carbidopa to levodopa in this product is 1:4. Each tablet contains 50mg carbidopa and 200mg levodopa. The daily dose of this product must be carefully adjusted and determined. During dose adjustment, patients should be closely monitored, especially the occurrence or aggravation of nausea or abnormal involuntary movement, including dyskinesia, chorea and dystonia. This product can be taken whole or half tablets. This method can maintain the sustained-release characteristics of the tablets and can not chew and crush the tablets. When taking this product, you can continue to take other standard anti Parkinson's disease drugs in addition to levodopa, but the dose needs to be adjusted. Because carbidopa can prevent the reversal of levodopa caused by pidoxin, this product can be used in patients receiving pidoxin supplementary treatment. At the same time, patients receiving pyridoxine supplement (vitamin B6) can take this product. Initial dose Patients not treated with levodopa: The recommended starting dose of this product is half a tablet twice a day. For patients who need more levodopa, take 1-4 half tablets a day in two times, generally well tolerated. This product can also be used for initial treatment when appropriate. The recommended starting dose of this product is 1 tablet 2 to 3 times a day. The starting dose of levodopa shall not be higher than 600mg per day or the interval between administration shall not be less than 6 hours. (see instructions for details)

    [adverse reactions] The most common adverse reaction is dyskinesia (an abnormal involuntary movement). Due to "on" Time (sometimes accompanied by dyskinesia) replaces the "off" time (this product can reduce this time). The incidence of dyskinesia using this product is slightly higher than that of ordinary tablets. Other common adverse reactions (more than 2%) were nausea, hallucination, insanity, dizziness, chorea and dry mouth. The less common adverse reactions (1-2%) were abnormal dreams, dystonia, drowsiness, insomnia, depression, weakness, vomiting and anorexia. (see instructions for details)

    [precautions] Patients undergoing levodopa treatment must stop levodopa for at least 12 hours before taking this product for treatment. In order to reduce adverse reactions, targeted treatment is necessary. See the usage and dosage section before starting treatment. If this product is used for treatment, the dose should provide at least about 25% of the dose of levodopa (see usage and dosage). Carbidopa does not reduce the adverse reactions caused by the central action of levodopa. Especially when nausea and vomiting are not dose limiting factors, compared with levodopa alone, during the treatment of this product, by allowing more levodopa to reach the brain, some adverse central nervous system (CNS) effects, such as dyskinesia, will occur at a lower dose and occur faster. Patients treated with this product may have more movement disorders. Dyskinesia is a common side effect of carbidopa and levodopa treatment. If involuntary exercise occurs, the dose may need to be reduced. All patients should be carefully observed to prevent depression with suicidal tendency. (see instructions for details)

    [taboo] Non selective monoamine oxidase (MAO) inhibitors cannot be taken simultaneously with this product. These inhibitors must be discontinued at least two weeks before starting treatment with this product. This product can be used in combination with selective type B monoamine oxidase inhibitor (such as selegilan hydrochloride) according to the dose recommended by the manufacturer. This product is forbidden for people who are known to be allergic to any component of this drug and patients with angle closure glaucoma. Because levodopa may activate malignant melanoma, it is forbidden for patients with suspected skin injury or a history of melanoma.

    [listing Permit Holder] Mercksharp & Dohme (Italy) Spa (sub packaged by Hangzhou MSD Pharmaceutical Co., Ltd.)

    [packaging unit] box

    [main ingredients] The main ingredients are carbidopa 50mg and levodopa 200mg.

    [character] This product is light pink and slightly yellow oval tablets.

    [applicable population] adult

    [medication for pregnant and lactating women] Pregnancy: no teratogenic effect was observed in a study in which mice were treated with up to 20 times the maximum recommended human dose. (see instructions for details)

    [medication for children] The safety and efficacy data of this product for infants and children have not been established, so it is not recommended for patients under the age of 18.

    [medication for elderly patients] Clinical studies have shown that this product has good safety and efficacy for this population, so there is no specific dose recommendation for this population.

    [storage] Avoid light and humidity.

    Praise degree

    zero%

      reminder

      Dear customer:

      In case of emergency, please call the ordering hotline400-086-5111Consult a health care professional pharmacist.

      Kazuo double DOPA sustained release tablets (Xining)

      ¥980.00

      reminder

      To ensure your privacy, please enter the verification code and click "confirm callback". Our customer service staff will call back the phone number you entered later!

      Please enter the correct verification code!
      Loding...
      Can't see clearly. Change one

      Dear customer:

      Your callback failed this time. Please re-enter the verification code to try. Thank you!